Form 4: Phathom CEO Basta Receives Significant Equity Awards

Phathom Pharmaceuticals' President and CEO, Steven L. Basta, was granted 251,034 restricted stock units and options for 226,156 shares, effective January 2, 2026.

Summary

• Steven L. Basta, President and CEO of Phathom Pharmaceuticals, Inc. (PHAT), received new equity awards.
• On January 2, 2026, Basta was granted 251,034 Restricted Stock Units (RSUs).
• These RSUs vest 1/3 on each of the first three anniversaries of January 2, 2026, contingent on continued service.
• Following this transaction, Basta beneficially owns 364,820 shares of common stock.
• Additionally, on January 2, 2026, Basta was granted stock options to purchase 226,156 shares of common stock.
• The exercise price for these options is $15.71 per share, and they expire on January 1, 2036.
• These stock options vest 1/48th monthly following January 2, 2026, contingent on continued service.
• Following this transaction, Basta beneficially owns 221,156 derivative securities (stock options).
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The filing indicates routine executive compensation, which is generally positive for aligning management incentives with long-term company performance, but it does not contain new operational or financial performance data.

Positives

• The significant equity grants align the interests of President and CEO Steven L. Basta with long-term shareholder value.
• The vesting schedules for both RSUs (three years) and stock options (four years, monthly) incentivize sustained leadership and performance.
• The use of a Rule 10b5-1(c) plan indicates a pre-arranged, compliant approach to equity transactions.

Negatives

• The issuance of new equity awards, particularly RSUs and stock options, represents potential future dilution for existing shareholders when they vest and are exercised.
• The 'price' of $0 for the RSUs and the grant of options at a specific strike price mean these are compensation, not open market purchases, which could be seen as a less direct vote of confidence than a personal cash investment.

Risks

• Vesting of both RSUs and stock options is subject to the Reporting Person's continued service to the Issuer through each vesting date. Failure to meet this condition would result in forfeiture of unvested awards.

Future Outlook

The long-term vesting schedules for the equity awards suggest a strategic intent to retain key management and align their performance with the company's sustained growth and future success over several years.

Industry Context

Executive compensation packages in the pharmaceutical and biotechnology sectors frequently include substantial equity components like RSUs and stock options. This practice is common for attracting and retaining top talent, particularly in companies focused on long-term drug development and commercialization, where success metrics often span many years.

Comparison to Industry Standards

• The structure of these equity grants, including a mix of RSUs and stock options with multi-year vesting schedules, is standard practice for executive compensation in the biotech and pharmaceutical industries.
• Companies in the pharmaceutical and biotechnology sectors frequently utilize similar long-term incentive plans to align executive interests with shareholder value, often tying vesting to continued service and sometimes performance metrics.
• The specific number of shares and exercise price would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this filing does not provide such comparative data.

Related Party Transactions

• Grant of 251,034 Restricted Stock Units to Steven L. Basta, President and CEO.
• Grant of options to purchase 226,156 shares of common stock to Steven L. Basta, President and CEO.

Stakeholder Impact

• Shareholders: Potential future dilution from the vesting and exercise of RSUs and stock options. However, the grants aim to align management's long-term interests with shareholder value.
• Employees: May set a precedent for executive compensation structures and long-term incentive plans within the company.
• Management (Steven L. Basta): Significant long-term incentive to drive company performance and increase share price, contingent on continued service.

Next Steps

• First anniversary of January 2, 2026: 1/3 of RSUs vest.
• Second anniversary of January 2, 2026: Another 1/3 of RSUs vest.
• Third anniversary of January 2, 2026: Final 1/3 of RSUs vest.
• Monthly following January 2, 2026: 1/48th of stock options vest over four years.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Steven L. Basta, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Equity Grant, Corporate Governance, Rule 10b5-1